While information on AML is currently limited, the co-expression of LAG-3 and PD-1 in solid tumors has been associated with a poor response to PD-1 blockade, and has been employed as a biomarker for predicting the success of immunotherapy [85,86]. The gene discussed is LAG3; the disease is acute myeloid leukemia.